Loading patent…
AssigneeThe Trustes of Columbia University in the City of New York
InventorTAKA-AKI SATO
Estimating the term…
This invention provides an isolated nucleic molecule encoding a polypeptide capable of binding a p75NTR receptor, and a purified version of said polypeptide capable of binding a p75NTR receptor. This invention provides a method of producing a purified polypeptide capable of binding a p75NTR receptor. This invention provides an antisense oligonucleotide having a nucleic acid sequence capable of specifically hybridizing to an mRNA molecule encoding the above described polypeptide. This invention provides a method producing a polypeptide capable of binding p75NT recptor into a suitable vector. This invention provides a method of inducing apoptosis, a method of determining physiological effects, a method for identifying an apoptosis inducing or inhibiting compound, a method for screening cDNA libraries of said polypeptide, a method to induce caspase-2 and caspase-3 activity to cleave poly (ADP-ribose) polymerase and fragment nuclear DNA in a cell, a method to inhibit NF-κB activation in a cell, a method to detect a neurodegenerative disease, a method of producing the isolated human HGR74 protein into a suitable vector, a pharmaceutical composition comprising a purified polypeptide capable of binding a p75NTR receptor and a pharmaceutically acceptable carrier and a method of identifying a compound which is an apoptosis inhibitor.
An isolated nucleic acid molecule encoding a polypeptide capable of binding with a p75NTR receptor.
An antisense oligonucleotide having a nucleic acid sequence capable of specifically hybridizing to an mRNA molecule encoding a polypeptide capable of binding p75NTR receptor.
A purified polypeptide capable of binding p75NTR receptor.
A method of inducing apoptosis in cells which comprises expressing a polypeptide capable of binding p75NTR receptor in the cells.
A method of inducing apoptosis in a subject which comprises expressing a polypeptide capable of binding p75NTR receptor in a subject.
A method of determining physiological effects of expressing varying levels of a polypeptide capable of binding p75NTR receptor in a transgenic nonhuman mammal which comprises producing a panel of transgenic non human mammal expressing a different amount of polypeptide capable of binding p75NTR receptor.
A method of producing a polypeptide capable of binding p75NTR receptor into a suitable vector which comprises:
A method of inducing apoptosis of cells in a subject comprising administering to the subject a purified polypeptide capable of binding p75NTR receptor in an amount effective to induce apoptosis.
A method of identifying a compound capable of inhibiting binding between p75NTR receptor and a polypeptide capable of binding p75NTR receptor comprising:
A method of identifying a compound capable of inhibiting binding between p75NTR receptor and a polypeptide capable of binding p75NTR receptor, where said binding forms a complex between p75NTR receptor and a polypeptide capable of binding p75NTR receptor, comprising:
A method for identifying an apoptosis inducing compound comprising:
A method for identifying an apoptosis inducing compound comprising:
A method for screening cDNA libraries of a polypeptide capable of binding p75NTR receptor using a yeast two-hybrid system using a p75NTR intracellular domain as a target.
A method to induce caspase-2 and caspase-3 activity to cleave poly (ADP-ribose) polymerase and fragment nuclear DNA in a cell by co-expression of polypeptide capable of binding p75NTR receptor and p75NTR.
A method to inhibit NF-KB activation in a cell with polypeptide capable of binding p75NTR receptor and p75NTR.
A method to detect a neurodegenerative disease in a subject by detecting expression levels of a polypeptide capable of binding p75NTR receptor and p75NTR.
A transgenic nonhuman mammal which comprises an isolated nucleic acid, encoding a human HGR74 protein, which is a DNA molecule.
A method of determining physiological effects of expressing varying levels of human HGR74 in a transgenic nonhuman mammal which comprises producing a panel of transgenic non human mammal expressing a different amount of human HGR74 protein.
A method of producing human HGR74 protein into a suitable vector which comprises:
A method of inducing apoptosis of cells in a subject comprising administering to the subject the purified human HGR74 protein in an amount effective to induce apoptosis.
A pharmaceutical composition comprising a purified human HGR74 protein and a pharmaceutically acceptable carrier.
A method for identifying an apoptosis inducing compound comprising:
A method for identifying an apoptosis inducing compound comprising:
A method for screening cDNA libraries human HGR74 protein using a yeast two-hybrid system using a p75NTR intracellular domain as a target.
A method to induce caspase-2 and caspase-3 activity to cleave poly (ADP-ribose) polymerase and fragment nuclear DNA in a cell by co-expression of human HGR74 protein and p75NTR.
A method to inhibit NF-KB activation in a cell with human HGR74 protein and p75NTR.
A method to detect a neurodegenerative disease in a subject by detecting expression levels of human HGR74 protein and p75NTR.
A method of identifying a compound, which is an apoptosis inhibitor, said compound is capable of inhibiting specific binding between polypeptide capable of binding p75NTR receptor and p75NTR receptor, so as to prevent apoptosis which comprises:
Dependencies are inferred from the claim text.